You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTipranavir
Accession NumberDB00932  (APRD01306)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionTipranavir is a sulfonamide-containing dyhydropyrone and a nonpeptidic protease inhibitor that targets the HIV protease. It is administered with ritonavir in combination therapy to treat HIV infections.
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AptivusCapsule250 mgOralBoehringer Ingelheim (Canada) Ltd Ltee2005-12-01Not applicableCanada
AptivusSolution100 mg/mLOralBoehringer Ingelheim Pharmaceuticals, Inc.2008-09-01Not applicableUs
AptivusCapsule, liquid filled250 mg/1OralBoehringer Ingelheim Pharmaceuticals, Inc.2005-07-01Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Tipranavir disodium
191150-83-1
Thumb
  • InChI Key: ZBWMQTUSVWBMQE-KPHXKKTMSA-M
  • Monoisotopic Mass: 646.17011633
  • Average Mass: 646.63
DBSALT001882
Categories
UNIIZZT404XD09
CAS number174484-41-4
WeightAverage: 602.664
Monoisotopic: 602.206227481
Chemical FormulaC31H33F3N2O5S
InChI KeySUJUHGSWHZTSEU-FYBSXPHGSA-N
InChI
InChI=1S/C31H33F3N2O5S/c1-3-16-30(17-15-21-9-6-5-7-10-21)19-26(37)28(29(38)41-30)25(4-2)22-11-8-12-24(18-22)36-42(39,40)27-14-13-23(20-35-27)31(32,33)34/h5-14,18,20,25,36-37H,3-4,15-17,19H2,1-2H3/t25-,30-/m1/s1
IUPAC Name
N-{3-[(1R)-1-[(6R)-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-5,6-dihydro-2H-pyran-3-yl]propyl]phenyl}-5-(trifluoromethyl)pyridine-2-sulfonamide
SMILES
[H][C@@](CC)(C1=CC(NS(=O)(=O)C2=NC=C(C=C2)C(F)(F)F)=CC=C1)C1=C(O)C[C@@](CCC)(CCC2=CC=CC=C2)OC1=O
Pharmacology
IndicationFor combination antiretroviral treatment of HIV-1 infected adult patients with evidence of viral replication, who are highly treatment-experienced or have HIV-1 strains resistant to multiple protease inhibitors.
Structured Indications
PharmacodynamicsTipranavir is a non-peptidic protease inhibitor (PI) of HIV. Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Nelfinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.
Mechanism of actionTipranavir (TPV) is a non-peptidic HIV-1 protease inhibitor that inhibits the processing of the viral Gag and Gag-Pol polyproteins in HIV-1 infected cells, thus preventing formation of mature virions. Two mechanisms are suggested in regards to the potency of tipranavir: 1. Tipravanir may bind to the active site of the protease enzyme with fewer hydrogen bonds than peptidic protease inhibitors, which results in increased flexibility, allowing it to fit into the active site of the enzyme in viruses that have become resistance to other protease inhibitors. This also enables tipranavir to adjust to amino acid substitutions at the active site. 2. Tipranavir's strong hydrogen bonding interaction with the amide backbone of the protease active site Asp30 may lead to its activity against resistant viruses.
TargetKindPharmacological actionActionsOrganismUniProt ID
Pol polyproteinProteinyes
inhibitor
Human immunodeficiency virus 1Q72874 details
Related Articles
AbsorptionAbsorption is limited, although no absolute quantification of absorption is available.
Volume of distributionNot Available
Protein bindingExtensive (> 99.9%), to both human serum albumin and α-1-acid glycoprotein.
Metabolism

Hepatic. In vitro metabolism studies with human liver microsomes indicated that CYP 3A4 is the predominant CYP enzyme involved in tipranavir metabolism.

Route of eliminationNot Available
Half life5-6 hours
ClearanceNot Available
ToxicityOral LD50 in rat is over 5,000 mg/kg. Side effects include thirst and hunger, unexplained weight loss, increased urination, fatigue, and dry, itchy skin.
Affected organisms
  • Human Immunodeficiency Virus
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of 1,10-Phenanthroline can be decreased when it is combined with Tipranavir.Experimental
3,4-DichloroisocoumarinThe serum concentration of 3,4-Dichloroisocoumarin can be decreased when it is combined with Tipranavir.Experimental
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE can be decreased when it is combined with Tipranavir.Experimental
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Tipranavir.Experimental, Illicit
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Tipranavir.Approved, Investigational
AbciximabTipranavir may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe serum concentration of Tipranavir can be increased when it is combined with Abiraterone.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Tipranavir.Approved, Investigational
AcenocoumarolTipranavir may increase the anticoagulant activities of Acenocoumarol.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Tipranavir.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Tipranavir.Withdrawn
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Tipranavir.Approved
Acetylsalicylic acidTipranavir may increase the antiplatelet activities of Acetylsalicylic acid.Approved, Vet Approved
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Tipranavir.Experimental
AjmalineThe metabolism of Ajmaline can be decreased when combined with Tipranavir.Approved
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Tipranavir.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Tipranavir.Approved, Investigational
AlogliptinThe serum concentration of Alogliptin can be decreased when it is combined with Tipranavir.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Alpha-1-proteinase inhibitor can be decreased when it is combined with Tipranavir.Approved
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Tipranavir.Approved, Illicit, Investigational
AlprenololThe metabolism of Alprenolol can be decreased when combined with Tipranavir.Approved, Withdrawn
AlprostadilTipranavir may increase the antiplatelet activities of Alprostadil.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Tipranavir.Experimental
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Tipranavir.Illicit, Withdrawn
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Tipranavir.Approved, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Tipranavir.Approved
AmiodaroneThe serum concentration of Amiodarone can be increased when it is combined with Tipranavir.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Tipranavir.Approved
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Tipranavir.Approved
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Tipranavir.Approved, Illicit
AmprenavirThe serum concentration of Amprenavir can be decreased when it is combined with Tipranavir.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Tipranavir.Approved
AnagrelideTipranavir may increase the antiplatelet activities of Anagrelide.Approved
AncrodTipranavir may increase the anticoagulant activities of Ancrod.Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Tipranavir.Approved
Antithrombin III humanThe serum concentration of Antithrombin III human can be decreased when it is combined with Tipranavir.Approved
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Tipranavir.Approved
AprepitantThe serum concentration of Tipranavir can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Tipranavir.Approved
AprotininThe serum concentration of Aprotinin can be decreased when it is combined with Tipranavir.Approved, Withdrawn
ArdeparinTipranavir may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Tipranavir.Approved, Investigational
ArgatrobanThe serum concentration of Argatroban can be decreased when it is combined with Tipranavir.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Tipranavir.Approved, Investigational
ArmodafinilThe metabolism of Tipranavir can be decreased when combined with Armodafinil.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Tipranavir.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Tipranavir.Approved, Withdrawn
AsunaprevirThe serum concentration of Asunaprevir can be decreased when it is combined with Tipranavir.Approved, Investigational
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Tipranavir.Approved, Investigational
AtomoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Tipranavir.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Tipranavir.Approved
AzelastineTipranavir may increase the antiplatelet activities of Azelastine.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Tipranavir.Investigational
BatimastatThe serum concentration of Batimastat can be decreased when it is combined with Tipranavir.Experimental
BazedoxifeneBazedoxifene may increase the dermatologic adverse activities of Tipranavir.Approved, Investigational
BecaplerminTipranavir may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BenazeprilThe serum concentration of Benazepril can be decreased when it is combined with Tipranavir.Approved, Investigational
BenzamidineThe serum concentration of Benzamidine can be decreased when it is combined with Tipranavir.Experimental
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Tipranavir.Approved
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Tipranavir.Approved
BepridilThe serum concentration of Bepridil can be increased when it is combined with Tipranavir.Approved, Withdrawn
BeraprostTipranavir may increase the antiplatelet activities of Beraprost.Investigational
BetaxololThe metabolism of Betaxolol can be decreased when combined with Tipranavir.Approved
BexaroteneThe serum concentration of Tipranavir can be decreased when it is combined with Bexarotene.Approved, Investigational
Bi201335The serum concentration of Bi201335 can be decreased when it is combined with Tipranavir.Investigational
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Tipranavir.Approved
BivalirudinThe serum concentration of Bivalirudin can be decreased when it is combined with Tipranavir.Approved, Investigational
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Tipranavir.Approved
BortezomibThe metabolism of Bortezomib can be decreased when combined with Tipranavir.Approved, Investigational
BosentanThe serum concentration of Tipranavir can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Tipranavir.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Tipranavir.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Tipranavir.Approved
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Tipranavir.Withdrawn
BufuralolThe metabolism of Bufuralol can be decreased when combined with Tipranavir.Experimental, Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Tipranavir.Approved, Investigational
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Tipranavir.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Tipranavir.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Tipranavir.Approved, Investigational
ButylphthalideTipranavir may increase the antiplatelet activities of Butylphthalide.Investigational
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Tipranavir.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Tipranavir.Approved
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Tipranavir.Approved
CandoxatrilThe serum concentration of Candoxatril can be decreased when it is combined with Tipranavir.Experimental
CandoxatrilatThe serum concentration of Candoxatrilat can be decreased when it is combined with Tipranavir.Experimental
CangrelorTipranavir may increase the antiplatelet activities of Cangrelor.Approved
CaptoprilThe serum concentration of Captopril can be decreased when it is combined with Tipranavir.Approved
CarbamazepineThe metabolism of Tipranavir can be increased when combined with Carbamazepine.Approved, Investigational
CariprazineThe metabolism of Cariprazine can be decreased when combined with Tipranavir.Approved
CarteololThe metabolism of Carteolol can be decreased when combined with Tipranavir.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Tipranavir.Approved, Investigational
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Tipranavir.Experimental
CelecoxibThe metabolism of Tipranavir can be decreased when combined with Celecoxib.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Tipranavir.Approved, Vet Approved
CeritinibThe serum concentration of Tipranavir can be increased when it is combined with Ceritinib.Approved
CertoparinTipranavir may increase the anticoagulant activities of Certoparin.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Tipranavir.Approved
ChloramphenicolThe metabolism of Tipranavir can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Tipranavir.Approved, Illicit
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Tipranavir.Approved, Vet Approved
ChlorotrianiseneChlorotrianisene may increase the dermatologic adverse activities of Tipranavir.Withdrawn
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Tipranavir.Approved
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Tipranavir.Approved, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Tipranavir.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Tipranavir.Approved
CholecalciferolThe metabolism of Tipranavir can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
ChymostatinThe serum concentration of Chymostatin can be decreased when it is combined with Tipranavir.Experimental
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Tipranavir.Experimental
CilastatinThe serum concentration of Cilastatin can be decreased when it is combined with Tipranavir.Approved
CilazaprilThe serum concentration of Cilazapril can be decreased when it is combined with Tipranavir.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Tipranavir.Approved
CimetidineThe metabolism of Tipranavir can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Tipranavir can be decreased when combined with Cinacalcet.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Tipranavir.Approved
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Tipranavir.Approved, Investigational, Withdrawn
CitalopramThe metabolism of Citalopram can be decreased when combined with Tipranavir.Approved
Citric AcidTipranavir may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Tipranavir.Approved
ClemastineThe metabolism of Tipranavir can be decreased when combined with Clemastine.Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Tipranavir.Approved
ClobazamThe metabolism of Tipranavir can be decreased when combined with Clobazam.Approved, Illicit
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Tipranavir.Approved, Vet Approved
ClonidineThe metabolism of Clonidine can be decreased when combined with Tipranavir.Approved
ClopidogrelTipranavir may increase the antiplatelet activities of Clopidogrel.Approved, Nutraceutical
ClotrimazoleThe metabolism of Tipranavir can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Clozapine can be decreased when combined with Tipranavir.Approved
CobicistatThe serum concentration of Tipranavir can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Tipranavir can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Tipranavir.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Tipranavir.Approved
ConivaptanThe serum concentration of Tipranavir can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensConjugated Equine Estrogens may increase the dermatologic adverse activities of Tipranavir.Approved
CrizotinibThe metabolism of Tipranavir can be decreased when combined with Crizotinib.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Tipranavir.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Tipranavir is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Tipranavir.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Tipranavir can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Tipranavir.Approved
DabrafenibThe serum concentration of Tipranavir can be decreased when it is combined with Dabrafenib.Approved
DalteparinTipranavir may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidTipranavir may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Tipranavir.Approved
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Tipranavir.Approved, Investigational
DarunavirThe serum concentration of Darunavir can be decreased when it is combined with Tipranavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Tipranavir.Approved
DasatinibThe serum concentration of Tipranavir can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Tipranavir.Approved
DeferasiroxThe serum concentration of Tipranavir can be decreased when it is combined with Deferasirox.Approved, Investigational
DefibrotideTipranavir may increase the antiplatelet activities of Defibrotide.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Tipranavir.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Tipranavir.Investigational
DesipramineThe metabolism of Desipramine can be decreased when combined with Tipranavir.Approved
DesirudinTipranavir may increase the anticoagulant activities of Desirudin.Approved
DesogestrelThe serum concentration of Desogestrel can be increased when it is combined with Tipranavir.Approved
DexamethasoneThe serum concentration of Tipranavir can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Tipranavir.Approved, Illicit, Withdrawn
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Tipranavir.Approved
DextranTipranavir may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Tipranavir may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Tipranavir may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Tipranavir may increase the anticoagulant activities of Dextran 75.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Tipranavir.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Tipranavir.Approved
DicoumarolTipranavir may increase the anticoagulant activities of Dicoumarol.Approved
DidanosineThe serum concentration of Didanosine can be decreased when it is combined with Tipranavir.Approved
DienestrolDienestrol may increase the dermatologic adverse activities of Tipranavir.Approved
DienogestThe serum concentration of Dienogest can be increased when it is combined with Tipranavir.Approved
DiethylstilbestrolDiethylstilbestrol may increase the dermatologic adverse activities of Tipranavir.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Tipranavir.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Tipranavir.Approved, Illicit
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Tipranavir.Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Tipranavir.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Tipranavir.Approved
DipyridamoleTipranavir may increase the antiplatelet activities of Dipyridamole.Approved
DisulfiramThe risk or severity of adverse effects can be increased when Disulfiram is combined with Tipranavir.Approved
DolasetronThe metabolism of Dolasetron can be decreased when combined with Tipranavir.Approved
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Tipranavir.Approved
DomperidoneThe metabolism of Domperidone can be decreased when combined with Tipranavir.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Tipranavir.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Tipranavir.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Tipranavir.Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Tipranavir.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Tipranavir.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Tipranavir.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Tipranavir.Approved, Investigational
DoxycyclineThe metabolism of Tipranavir can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Dronedarone can be decreased when combined with Tipranavir.Approved
DrospirenoneThe serum concentration of Drospirenone can be increased when it is combined with Tipranavir.Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Tipranavir.Approved
DuloxetineThe serum concentration of Duloxetine can be increased when it is combined with Tipranavir.Approved
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Tipranavir.Approved
EcabetThe serum concentration of Ecabet can be decreased when it is combined with Tipranavir.Approved, Investigational
Edetic AcidTipranavir may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanThe serum concentration of Edoxaban can be decreased when it is combined with Tipranavir.Approved
EfavirenzThe serum concentration of Tipranavir can be decreased when it is combined with Efavirenz.Approved, Investigational
ElafinThe serum concentration of Elafin can be decreased when it is combined with Tipranavir.Investigational
EletriptanThe metabolism of Eletriptan can be decreased when combined with Tipranavir.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Tipranavir.Approved
EluxadolineThe serum concentration of Eluxadoline can be increased when it is combined with Tipranavir.Approved
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Tipranavir.Approved
EnalaprilThe serum concentration of Enalapril can be decreased when it is combined with Tipranavir.Approved, Vet Approved
EnalaprilatThe serum concentration of Enalaprilat can be decreased when it is combined with Tipranavir.Approved
EnalkirenThe serum concentration of Enalkiren can be decreased when it is combined with Tipranavir.Experimental
EncainideThe metabolism of Encainide can be decreased when combined with Tipranavir.Approved, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Tipranavir.Investigational
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Tipranavir.Approved, Investigational
EnoxaparinTipranavir may increase the anticoagulant activities of Enoxaparin.Approved
EnzalutamideThe serum concentration of Tipranavir can be decreased when it is combined with Enzalutamide.Approved
EpinastineTipranavir may increase the antiplatelet activities of Epinastine.Approved, Investigational
eplivanserineTipranavir may increase the antiplatelet activities of eplivanserine.Investigational
EpoprostenolTipranavir may increase the antiplatelet activities of Epoprostenol.Approved
EptifibatideTipranavir may increase the antiplatelet activities of Eptifibatide.Approved, Investigational
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Tipranavir.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Tipranavir.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Tipranavir.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Tipranavir.Approved, Investigational
ErythromycinThe metabolism of Tipranavir can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Tipranavir.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Tipranavir can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Tipranavir.Investigational
EsomeprazoleThe serum concentration of Esomeprazole can be decreased when it is combined with Tipranavir.Approved, Investigational
EstradiolEstradiol may increase the dermatologic adverse activities of Tipranavir.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Tipranavir.Approved
EstriolEstriol may increase the dermatologic adverse activities of Tipranavir.Approved, Vet Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Tipranavir.Approved
EstroneEstrone may increase the dermatologic adverse activities of Tipranavir.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Tipranavir.Approved
Ethinyl EstradiolEthinyl Estradiol may increase the dermatologic adverse activities of Tipranavir.Approved
Ethyl biscoumacetateTipranavir may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Tipranavir.Approved, Illicit
Ethynodiol diacetateThe serum concentration of Ethynodiol diacetate can be increased when it is combined with Tipranavir.Approved
EtonogestrelThe serum concentration of Etonogestrel can be increased when it is combined with Tipranavir.Approved, Investigational
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Tipranavir.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Tipranavir.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Tipranavir.Approved, Investigational
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tipranavir.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Tipranavir.Approved, Investigational
FlecainideThe serum concentration of Flecainide can be increased when it is combined with Tipranavir.Approved, Withdrawn
FluconazoleThe serum concentration of Tipranavir can be increased when it is combined with Fluconazole.Approved
FluindioneTipranavir may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Tipranavir.Approved
FluoxetineThe metabolism of Tipranavir can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Tipranavir.Approved
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be increased when it is combined with Tipranavir.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Tipranavir.Approved
FluvoxamineThe metabolism of Tipranavir can be decreased when combined with Fluvoxamine.Approved, Investigational
FondaparinuxTipranavir may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumTipranavir may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Tipranavir.Approved, Investigational
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Tipranavir.Approved
FosaprepitantThe serum concentration of Tipranavir can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Fosinopril can be decreased when it is combined with Tipranavir.Approved
FosphenytoinThe serum concentration of Tipranavir can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Tipranavir can be increased when it is combined with Fusidic Acid.Approved
GabexateThe serum concentration of Gabexate can be decreased when it is combined with Tipranavir.Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Tipranavir.Approved
GarlicThe serum concentration of Tipranavir can be decreased when it is combined with Garlic.Approved
GefitinibThe metabolism of Gefitinib can be decreased when combined with Tipranavir.Approved, Investigational
GeldanamycinThe serum concentration of Geldanamycin can be decreased when it is combined with Tipranavir.Experimental
GemfibrozilThe metabolism of Tipranavir can be decreased when combined with Gemfibrozil.Approved
GenisteinGenistein may increase the dermatologic adverse activities of Tipranavir.Investigational
GestodeneThe serum concentration of Gestodene can be increased when it is combined with Tipranavir.Approved
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Tipranavir.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Tipranavir.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Tipranavir.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Tipranavir.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Tipranavir.Approved
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Tipranavir.Approved
GM6001The serum concentration of GM6001 can be decreased when it is combined with Tipranavir.Experimental
GranisetronThe metabolism of Granisetron can be decreased when combined with Tipranavir.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Tipranavir.Investigational
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Tipranavir.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Tipranavir.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Tipranavir.Approved, Vet Approved
HeparinTipranavir may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolHexestrol may increase the dermatologic adverse activities of Tipranavir.Withdrawn
HirulogThe serum concentration of Hirulog can be decreased when it is combined with Tipranavir.Experimental
HydrocodoneThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Tipranavir resulting in a loss in efficacy.Approved, Illicit
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Tipranavir.Approved, Illicit
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Tipranavir.Approved
IbudilastTipranavir may increase the antiplatelet activities of Ibudilast.Approved, Investigational
Icosapent ethylTipranavir may increase the antiplatelet activities of Icosapent ethyl.Approved, Nutraceutical
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Tipranavir.Approved
IdelalisibThe serum concentration of Tipranavir can be increased when it is combined with Idelalisib.Approved
idraparinuxThe serum concentration of idraparinux can be decreased when it is combined with Tipranavir.Investigational
IfenprodilTipranavir may increase the antiplatelet activities of Ifenprodil.Approved, Withdrawn
IloperidoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Tipranavir.Approved
IloprostTipranavir may increase the antiplatelet activities of Iloprost.Approved, Investigational
ImatinibThe metabolism of Imatinib can be decreased when combined with Tipranavir.Approved
ImidaprilThe serum concentration of Imidapril can be decreased when it is combined with Tipranavir.Investigational
ImipramineThe metabolism of Imipramine can be decreased when combined with Tipranavir.Approved
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Tipranavir.Approved
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Tipranavir.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Tipranavir.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Tipranavir.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Tipranavir.Approved
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Tipranavir.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Tipranavir.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Tipranavir.Approved
IsavuconazoniumThe metabolism of Tipranavir can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe serum concentration of Isoflurophate can be decreased when it is combined with Tipranavir.Approved, Withdrawn
IsoniazidThe metabolism of Tipranavir can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Tipranavir can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Itraconazole can be increased when it is combined with Tipranavir.Approved, Investigational
IvacaftorThe serum concentration of Tipranavir can be increased when it is combined with Ivacaftor.Approved
IxazomibThe serum concentration of Ixazomib can be decreased when it is combined with Tipranavir.Approved
KetanserinTipranavir may increase the antiplatelet activities of Ketanserin.Investigational
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Tipranavir.Approved, Investigational
KetoconazoleThe metabolism of Tipranavir can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe metabolism of Labetalol can be decreased when combined with Tipranavir.Approved
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Tipranavir.Approved, Investigational
LepirudinThe serum concentration of Lepirudin can be decreased when it is combined with Tipranavir.Approved
LevodopaThe metabolism of Levodopa can be decreased when combined with Tipranavir.Approved
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Tipranavir.Approved
LevonorgestrelThe serum concentration of Levonorgestrel can be increased when it is combined with Tipranavir.Approved, Investigational
LidocaineThe metabolism of Lidocaine can be decreased when combined with Tipranavir.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Tipranavir.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Tipranavir.Approved
LisinoprilThe serum concentration of Lisinopril can be decreased when it is combined with Tipranavir.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Tipranavir.Approved
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Tipranavir.Approved
LomustineThe metabolism of Lomustine can be decreased when combined with Tipranavir.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Tipranavir.Approved
LopinavirThe serum concentration of Lopinavir can be decreased when it is combined with Tipranavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Tipranavir.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Tipranavir.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Tipranavir.Approved, Investigational
LuliconazoleThe serum concentration of Tipranavir can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Tipranavir can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Tipranavir can be decreased when combined with Lumefantrine.Approved
LynestrenolThe serum concentration of Lynestrenol can be increased when it is combined with Tipranavir.Investigational
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Tipranavir.Approved
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Tipranavir.Approved, Investigational
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Tipranavir.Investigational, Withdrawn
MequitazineThe serum concentration of Mequitazine can be increased when it is combined with Tipranavir.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Tipranavir.Approved
MestranolMestranol may increase the dermatologic adverse activities of Tipranavir.Approved
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Tipranavir.Approved
MethadoneThe serum concentration of Methadone can be decreased when it is combined with Tipranavir.Approved
MethallenestrilMethallenestril may increase the dermatologic adverse activities of Tipranavir.Experimental
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Tipranavir.Approved, Illicit
MethotrimeprazineThe metabolism of Methotrimeprazine can be decreased when combined with Tipranavir.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Tipranavir.Approved, Vet Approved
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Tipranavir.Approved, Investigational
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Tipranavir.Approved, Illicit, Withdrawn
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Tipranavir.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Tipranavir.Approved, Investigational
MetronidazoleThe risk or severity of adverse effects can be increased when Metronidazole is combined with Tipranavir.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Tipranavir.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Tipranavir.Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Tipranavir.Approved, Illicit
MifepristoneThe serum concentration of Tipranavir can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Tipranavir.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Tipranavir.Approved
MilrinoneTipranavir may increase the antiplatelet activities of Milrinone.Approved
MinaprineThe metabolism of Minaprine can be decreased when combined with Tipranavir.Approved
MirabegronThe metabolism of Mirabegron can be decreased when combined with Tipranavir.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Tipranavir.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Tipranavir.Approved, Investigational
MitotaneThe serum concentration of Tipranavir can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Tipranavir.Approved
ModafinilThe serum concentration of Tipranavir can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe serum concentration of Moexipril can be decreased when it is combined with Tipranavir.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Tipranavir.Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline can be decreased when it is combined with Tipranavir.Experimental
NadroparinTipranavir may increase the anticoagulant activities of Nadroparin.Approved
NafamostatThe serum concentration of Nafamostat can be decreased when it is combined with Tipranavir.Investigational
NafcillinThe serum concentration of Tipranavir can be decreased when it is combined with Nafcillin.Approved
NaftopidilTipranavir may increase the antiplatelet activities of Naftopidil.Investigational
NateglinideThe metabolism of Nateglinide can be decreased when combined with Tipranavir.Approved, Investigational
NCX 4016The serum concentration of NCX 4016 can be decreased when it is combined with Tipranavir.Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Tipranavir.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Tipranavir.Approved, Withdrawn
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Tipranavir.Approved
NetupitantThe serum concentration of Tipranavir can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Tipranavir can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Nicardipine can be decreased when combined with Tipranavir.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Tipranavir.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Tipranavir.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Tipranavir.Approved
NilotinibThe metabolism of Tipranavir can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideTipranavir may increase the antiplatelet activities of Nimesulide.Approved, Withdrawn
NitroaspirinThe serum concentration of Nitroaspirin can be decreased when it is combined with Tipranavir.Investigational
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Tipranavir.Approved, Vet Approved
NorelgestrominThe serum concentration of Norelgestromin can be increased when it is combined with Tipranavir.Approved
NorgestimateThe serum concentration of Norgestimate can be increased when it is combined with Tipranavir.Approved
NorgestrelThe serum concentration of Norgestrel can be increased when it is combined with Tipranavir.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Tipranavir.Approved
OlanzapineThe metabolism of Olanzapine can be decreased when combined with Tipranavir.Approved, Investigational
OlaparibThe metabolism of Tipranavir can be decreased when combined with Olaparib.Approved
OmapatrilatThe serum concentration of Omapatrilat can be decreased when it is combined with Tipranavir.Investigational
OmeprazoleThe serum concentration of Omeprazole can be decreased when it is combined with Tipranavir.Approved, Investigational, Vet Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Tipranavir.Approved
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Tipranavir.Investigational
OsimertinibThe serum concentration of Tipranavir can be increased when it is combined with Osimertinib.Approved
OtamixabanThe serum concentration of Otamixaban can be decreased when it is combined with Tipranavir.Investigational
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Tipranavir.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Tipranavir.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Tipranavir can be increased when it is combined with Palbociclib.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Tipranavir.Approved, Investigational
PanobinostatThe serum concentration of Tipranavir can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Pantoprazole can be decreased when it is combined with Tipranavir.Approved
ParoxetineThe metabolism of Tipranavir can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe metabolism of Pazopanib can be decreased when combined with Tipranavir.Approved
Peginterferon alfa-2bThe serum concentration of Tipranavir can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentamidineThe metabolism of Pentamidine can be decreased when combined with Tipranavir.Approved
PentobarbitalThe metabolism of Tipranavir can be increased when combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfateTipranavir may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PentoxifyllineTipranavir may increase the antiplatelet activities of Pentoxifylline.Approved, Investigational
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Tipranavir.Approved
PerindoprilThe serum concentration of Perindopril can be decreased when it is combined with Tipranavir.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Tipranavir.Approved
PethidineThe risk or severity of adverse effects can be increased when Tipranavir is combined with Pethidine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Tipranavir.Withdrawn
PhenforminThe metabolism of Phenformin can be decreased when combined with Tipranavir.Approved, Withdrawn
PhenindioneTipranavir may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe serum concentration of Tipranavir can be decreased when it is combined with Phenobarbital.Approved
PhenprocoumonTipranavir may increase the anticoagulant activities of Phenprocoumon.Approved
PhenytoinThe serum concentration of Tipranavir can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Phosphoramidon can be decreased when it is combined with Tipranavir.Experimental
PimozideThe serum concentration of Pimozide can be increased when it is combined with Tipranavir.Approved
PindololThe metabolism of Pindolol can be decreased when combined with Tipranavir.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Tipranavir.Approved, Investigational
PiperazineThe metabolism of Piperazine can be decreased when combined with Tipranavir.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Tipranavir.Approved
Polyestradiol phosphatePolyestradiol phosphate may increase the dermatologic adverse activities of Tipranavir.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Tipranavir.Approved
PosaconazoleThe metabolism of Tipranavir can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Tipranavir.Approved, Investigational
PrasugrelTipranavir may increase the antiplatelet activities of Prasugrel.Approved
PrimidoneThe metabolism of Tipranavir can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Prinomastat can be decreased when it is combined with Tipranavir.Investigational
ProcainamideThe metabolism of Procainamide can be decreased when combined with Tipranavir.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Tipranavir.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Tipranavir.Approved, Vet Approved
PromazineThe metabolism of Tipranavir can be decreased when combined with Promazine.Approved, Vet Approved
PromestrienePromestriene may increase the dermatologic adverse activities of Tipranavir.Investigational
PromethazineThe metabolism of Promethazine can be decreased when combined with Tipranavir.Approved
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Tipranavir.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Tipranavir.Approved, Investigational, Vet Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Tipranavir.Approved, Investigational
Protein CTipranavir may increase the anticoagulant activities of Protein C.Approved
Protein S humanTipranavir may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeTipranavir may increase the anticoagulant activities of Protocatechualdehyde.Approved
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Tipranavir.Approved
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Tipranavir.Approved
QuetiapineThe metabolism of Quetiapine can be decreased when combined with Tipranavir.Approved
QuinaprilThe serum concentration of Quinapril can be decreased when it is combined with Tipranavir.Approved, Investigational
QuinestrolQuinestrol may increase the dermatologic adverse activities of Tipranavir.Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Tipranavir.Approved
QuinineThe metabolism of Quinine can be decreased when combined with Tipranavir.Approved
RabeprazoleThe serum concentration of Rabeprazole can be decreased when it is combined with Tipranavir.Approved, Investigational
RacecadotrilThe serum concentration of Racecadotril can be decreased when it is combined with Tipranavir.Investigational
RaltegravirThe serum concentration of Raltegravir can be decreased when it is combined with Tipranavir.Approved
RamatrobanTipranavir may increase the antiplatelet activities of Ramatroban.Investigational
RamiprilThe serum concentration of Ramipril can be decreased when it is combined with Tipranavir.Approved
RanitidineThe metabolism of Ranitidine can be decreased when combined with Tipranavir.Approved
RanolazineThe metabolism of Tipranavir can be decreased when combined with Ranolazine.Approved, Investigational
RemikirenThe serum concentration of Remikiren can be decreased when it is combined with Tipranavir.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Tipranavir.Approved, Withdrawn
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Tipranavir.Approved, Investigational
repinotanThe metabolism of repinotan can be decreased when combined with Tipranavir.Investigational
ResveratrolTipranavir may increase the antiplatelet activities of Resveratrol.Experimental, Investigational
ReviparinTipranavir may increase the anticoagulant activities of Reviparin.Approved
RidogrelTipranavir may increase the antiplatelet activities of Ridogrel.Approved
RifabutinThe serum concentration of the active metabolites of Rifabutin can be increased when Rifabutin is used in combination with Tipranavir.Approved
RifampicinThe serum concentration of Tipranavir can be decreased when it is combined with Rifampicin.Approved
RifapentineThe metabolism of Tipranavir can be increased when combined with Rifapentine.Approved
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Tipranavir.Approved
RisperidoneThe metabolism of Risperidone can be decreased when combined with Tipranavir.Approved, Investigational
RitonavirThe serum concentration of Ritonavir can be decreased when it is combined with Tipranavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Tipranavir.Approved
RolapitantThe metabolism of Tipranavir can be decreased when combined with Rolapitant.Approved
RopiniroleThe metabolism of Tipranavir can be decreased when combined with Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Tipranavir.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Tipranavir.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Tipranavir.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Tipranavir.Approved
S EquolS Equol may increase the dermatologic adverse activities of Tipranavir.Investigational
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Tipranavir.Approved
SaquinavirThe serum concentration of Saquinavir can be decreased when it is combined with Tipranavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Tipranavir.Approved
SCH-530348Tipranavir may increase the antiplatelet activities of SCH-530348.Investigational
SecoisolariciresinolSecoisolariciresinol may increase the dermatologic adverse activities of Tipranavir.Investigational
SertindoleThe metabolism of Sertindole can be decreased when combined with Tipranavir.Approved, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Tipranavir.Approved
SevofluraneTipranavir may increase the antiplatelet activities of Sevoflurane.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Tipranavir.Approved, Investigational
SiltuximabThe serum concentration of Tipranavir can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Tipranavir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Tipranavir.Approved
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Tipranavir.Approved, Investigational
SparteineThe metabolism of Sparteine can be decreased when combined with Tipranavir.Experimental
SpiraprilThe serum concentration of Spirapril can be decreased when it is combined with Tipranavir.Approved
SRT501Tipranavir may increase the antiplatelet activities of SRT501.Investigational
St. John's WortThe serum concentration of Tipranavir can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Tipranavir can be increased when it is combined with Stiripentol.Approved
SulfisoxazoleThe metabolism of Tipranavir can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulodexideTipranavir may increase the anticoagulant activities of Sulodexide.Approved, Investigational
Synthetic Conjugated Estrogens, ASynthetic Conjugated Estrogens, A may increase the dermatologic adverse activities of Tipranavir.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may increase the dermatologic adverse activities of Tipranavir.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Tipranavir.Approved, Investigational
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Tipranavir.Approved, Investigational
TAK-390MRThe serum concentration of TAK-390MR can be decreased when it is combined with Tipranavir.Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Tipranavir resulting in a loss in efficacy.Approved
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Tipranavir.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Tipranavir.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Tipranavir.Investigational, Withdrawn
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Tipranavir.Approved
TelithromycinThe metabolism of Tipranavir can be decreased when combined with Telithromycin.Approved
TemocaprilThe serum concentration of Temocapril can be decreased when it is combined with Tipranavir.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Tipranavir is combined with Temsirolimus.Approved
TenofovirThe serum concentration of Tipranavir can be decreased when it is combined with Tenofovir.Approved, Investigational
TerbinafineThe metabolism of Tipranavir can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Tipranavir.Withdrawn
TesmilifeneTipranavir may increase the antiplatelet activities of Tesmilifene.Investigational
TetrabenazineThe serum concentration of Tetrabenazine can be increased when it is combined with Tipranavir.Approved
TheophyllineThe metabolism of Theophylline can be decreased when combined with Tipranavir.Approved
ThiazolidinedioneThe therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Tipranavir.Investigational
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Tipranavir.Approved
ThiorphanThe serum concentration of Thiorphan can be decreased when it is combined with Tipranavir.Experimental
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Tipranavir.Approved
TiboloneTibolone may increase the dermatologic adverse activities of Tipranavir.Approved
TiclopidineTipranavir may increase the antiplatelet activities of Ticlopidine.Approved
TimololThe metabolism of Timolol can be decreased when combined with Tipranavir.Approved
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Tipranavir.Approved
TirofibanTipranavir may increase the antiplatelet activities of Tirofiban.Approved
TocilizumabThe serum concentration of Tipranavir can be decreased when it is combined with Tocilizumab.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Tipranavir.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Tipranavir.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Tipranavir.Approved, Investigational
TopiramateThe metabolism of Tipranavir can be decreased when combined with Topiramate.Approved
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Tipranavir.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Tipranavir.Approved, Investigational
TrandolaprilThe serum concentration of Trandolapril can be decreased when it is combined with Tipranavir.Approved
TranilastTipranavir may increase the antiplatelet activities of Tranilast.Approved, Investigational
TranylcypromineThe metabolism of Tipranavir can be decreased when combined with Tranylcypromine.Approved
TrapidilTipranavir may increase the antiplatelet activities of Trapidil.Approved
TrazodoneThe serum concentration of Trazodone can be increased when it is combined with Tipranavir.Approved, Investigational
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Tipranavir.Approved
TriflusalTipranavir may increase the antiplatelet activities of Triflusal.Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Tipranavir.Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Tipranavir.Withdrawn
UbenimexThe serum concentration of Ubenimex can be decreased when it is combined with Tipranavir.Experimental
UlinastatinThe serum concentration of Ulinastatin can be decreased when it is combined with Tipranavir.Investigational
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Tipranavir.Approved
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Tipranavir.Approved, Investigational
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Tipranavir.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Tipranavir.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Tipranavir.Approved
VildagliptinThe serum concentration of Vildagliptin can be decreased when it is combined with Tipranavir.Approved, Investigational
VinblastineThe metabolism of Vinblastine can be decreased when combined with Tipranavir.Approved
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Tipranavir.Approved, Investigational
Vitamin EThe risk or severity of adverse effects can be increased when Tipranavir is combined with Vitamin E.Approved, Nutraceutical, Vet Approved
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Tipranavir.Approved, Investigational
VorapaxarTipranavir may increase the antiplatelet activities of Vorapaxar.Approved
VoriconazoleThe metabolism of Tipranavir can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Tipranavir.Approved
WarfarinTipranavir may increase the anticoagulant activities of Warfarin.Approved
XimelagatranThe serum concentration of Ximelagatran can be decreased when it is combined with Tipranavir.Approved, Investigational, Withdrawn
Ym150The serum concentration of Ym150 can be decreased when it is combined with Tipranavir.Investigational
YohimbineThe metabolism of Yohimbine can be decreased when combined with Tipranavir.Approved, Vet Approved
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Tipranavir.Approved
ZeranolZeranol may increase the dermatologic adverse activities of Tipranavir.Vet Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Tipranavir.Approved
ZiprasidoneThe metabolism of Tipranavir can be decreased when combined with Ziprasidone.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Tipranavir.Approved
ZuclopenthixolThe metabolism of Zuclopenthixol can be decreased when combined with Tipranavir.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Franz Klingler, “Enantioselective hydrogenation of intermediates in the synthesis of tipranavir.” U.S. Patent US20040224990, issued November 11, 2004.

US20040224990
General References
  1. Doyon L, Tremblay S, Bourgon L, Wardrop E, Cordingley MG: Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir. Antiviral Res. 2005 Oct;68(1):27-35. [PubMed:16122817 ]
  2. Authors unspecified: Tipranavir: PNU 140690, tipranivir. Drugs R D. 2006;7(1):55-62. [PubMed:16620137 ]
  3. Temesgen Z, Feinberg J: Tipranavir: a new option for the treatment of drug-resistant HIV infection. Clin Infect Dis. 2007 Sep 15;45(6):761-9. Epub 2007 Aug 7. [PubMed:17712762 ]
  4. Luna B, Townsend MU: Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance. Clin Ther. 2007 Nov;29(11):2309-18. [PubMed:18158073 ]
External Links
ATC CodesJ05AE09
AHFS Codes
  • 08:18.08.08
PDB EntriesNot Available
FDA labelDownload (388 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9066
Blood Brain Barrier-0.6801
Caco-2 permeable-0.6103
P-glycoprotein substrateSubstrate0.5277
P-glycoprotein inhibitor INon-inhibitor0.5057
P-glycoprotein inhibitor IINon-inhibitor0.9249
Renal organic cation transporterNon-inhibitor0.9277
CYP450 2C9 substrateNon-substrate0.8364
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.5143
CYP450 1A2 substrateNon-inhibitor0.6708
CYP450 2C9 inhibitorNon-inhibitor0.5711
CYP450 2D6 inhibitorNon-inhibitor0.8485
CYP450 2C19 inhibitorNon-inhibitor0.5383
CYP450 3A4 inhibitorNon-inhibitor0.5442
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5317
Ames testNon AMES toxic0.6078
CarcinogenicityNon-carcinogens0.728
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5773 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8277
hERG inhibition (predictor II)Non-inhibitor0.702
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Boehringer ingelheim pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
CapsuleOral250 mg
Capsule, liquid filledOral250 mg/1
SolutionOral100 mg/mL
Prices
Unit descriptionCostUnit
Aptivus 120 250 mg capsule Bottle1271.8USD bottle
Aptivus 250 mg capsule10.19USD capsule
Aptivus 100 mg/ml solution4.29USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2187523 No2006-11-212015-05-04Canada
CA2294033 No2007-01-092018-07-27Canada
US5852195 Yes1999-12-222019-12-22Us
US6147095 Yes2000-04-292020-04-29Us
US6169181 No1994-05-062014-05-06Us
US6231887 Yes1999-01-272019-01-27Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityInsolubleNot Available
logP6.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000205 mg/mLALOGPS
logP6.29ALOGPS
logP7.14ChemAxon
logS-6.5ALOGPS
pKa (Strongest Acidic)5.92ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area105.59 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity154.57 m3·mol-1ChemAxon
Polarizability60.87 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as linear diarylheptanoids. These are diarylheptanoids with an open heptane chain. The two aromatic rings are linked only by the heptane chain.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassDiarylheptanoids
Sub ClassLinear diarylheptanoids
Direct ParentLinear diarylheptanoids
Alternative Parents
Substituents
  • Linear 1,7-diphenylheptane skeleton
  • Sulfanilide
  • Pyridine-2-sulfonamide
  • Phenylpropane
  • Dihydropyranone
  • Benzenoid
  • Pyridine
  • Pyran
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Vinylogous acid
  • Alpha,beta-unsaturated carboxylic ester
  • Enoate ester
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Lactone
  • Carboxylic acid ester
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Enol
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Alkyl halide
  • Alkyl fluoride
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human immunodeficiency virus 1
Pharmacological action
yes
Actions
inhibitor
General Function:
Aspartic-type endopeptidase activity
Specific Function:
Not Available
Gene Name:
pol
Uniprot ID:
Q72874
Molecular Weight:
10778.7 Da
References
  1. Koh Y, Matsumi S, Das D, Amano M, Davis DA, Li J, Leschenko S, Baldridge A, Shioda T, Yarchoan R, Ghosh AK, Mitsuya H: Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. J Biol Chem. 2007 Sep 28;282(39):28709-20. Epub 2007 Jul 17. [PubMed:17635930 ]
  2. Tenore SB, Ferreira PR: The Place of protease inhibitors in antiretroviral treatment. Braz J Infect Dis. 2009 Oct;13(5):371-4. doi: 10.1590/S1413-86702009000500012. [PubMed:20428639 ]
  3. Muzammil S, Armstrong AA, Kang LW, Jakalian A, Bonneau PR, Schmelmer V, Amzel LM, Freire E: Unique thermodynamic response of tipranavir to human immunodeficiency virus type 1 protease drug resistance mutations. J Virol. 2007 May;81(10):5144-54. Epub 2007 Mar 14. [PubMed:17360759 ]
  4. Hsieh SM, Chang SY, Hung CC, Sheng WH, Chen MY, Chang SC: Impact of first-line protease inhibitors on predicted resistance to tipranavir in HIV-1-infected patients with virological failure. BMC Infect Dis. 2009 Sep 14;9:154. doi: 10.1186/1471-2334-9-154. [PubMed:19751502 ]
  5. Temesgen Z, Feinberg J: Tipranavir: a new option for the treatment of drug-resistant HIV infection. Clin Infect Dis. 2007 Sep 15;45(6):761-9. Epub 2007 Aug 7. [PubMed:17712762 ]
  6. Luna B, Townsend MU: Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance. Clin Ther. 2007 Nov;29(11):2309-18. [PubMed:18158073 ]
  7. Croom KF, Keam SJ: Tipranavir: a ritonavir-boosted protease inhibitor. Drugs. 2005;65(12):1669-77; discussion 1678-9. [PubMed:16060700 ]
  8. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Temesgen Z, Feinberg J: Tipranavir: a new option for the treatment of drug-resistant HIV infection. Clin Infect Dis. 2007 Sep 15;45(6):761-9. Epub 2007 Aug 7. [PubMed:17712762 ]
  2. Luna B, Townsend MU: Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance. Clin Ther. 2007 Nov;29(11):2309-18. [PubMed:18158073 ]
  3. Li F, Wang L, Guo GL, Ma X: Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice. Drug Metab Dispos. 2010 May;38(5):871-8. doi: 10.1124/dmd.109.030817. Epub 2010 Jan 26. [PubMed:20103582 ]
  4. Dumond JB, Vourvahis M, Rezk NL, Patterson KB, Tien HC, White N, Jennings SH, Choi SO, Li J, Wagner MJ, La-Beck NM, Drulak M, Sabo JP, Castles MA, Macgregor TR, Kashuba AD: A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther. 2010 Jun;87(6):735-42. doi: 10.1038/clpt.2009.253. Epub 2010 Feb 10. [PubMed:20147896 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Li F, Wang L, Guo GL, Ma X: Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice. Drug Metab Dispos. 2010 May;38(5):871-8. doi: 10.1124/dmd.109.030817. Epub 2010 Jan 26. [PubMed:20103582 ]
  2. Dumond JB, Vourvahis M, Rezk NL, Patterson KB, Tien HC, White N, Jennings SH, Choi SO, Li J, Wagner MJ, La-Beck NM, Drulak M, Sabo JP, Castles MA, Macgregor TR, Kashuba AD: A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther. 2010 Jun;87(6):735-42. doi: 10.1038/clpt.2009.253. Epub 2010 Feb 10. [PubMed:20147896 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Li F, Wang L, Guo GL, Ma X: Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice. Drug Metab Dispos. 2010 May;38(5):871-8. doi: 10.1124/dmd.109.030817. Epub 2010 Jan 26. [PubMed:20103582 ]
  2. Dumond JB, Vourvahis M, Rezk NL, Patterson KB, Tien HC, White N, Jennings SH, Choi SO, Li J, Wagner MJ, La-Beck NM, Drulak M, Sabo JP, Castles MA, Macgregor TR, Kashuba AD: A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther. 2010 Jun;87(6):735-42. doi: 10.1038/clpt.2009.253. Epub 2010 Feb 10. [PubMed:20147896 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 07, 2016 03:54